Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07568964
Starting soon Not applicable

Evaluation of Probiotics' Effect on Atrial Fibrillation Recurrence in Patients Undergoing Cardioversion

NCT07568964 · tracked via the Priya Life Science Egypt tracker
Sponsor
Ain Shams University
Phase
Not applicable
Started
2026-05-10
Last updated
2026-05-06

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

Anticoagulant TherapyProbiotics capsules

Anticoagulant Therapy: Drug: The standard of care for AF management directly following cardioversion Include anticoagulant therapy for at least 4 weeks, rate control therapy, rhythm control therapy, or both as per clinical and guideline decisions.

Probiotics capsules: Probiotics at a of dose 25 billion / 1 capsule will be orally administered daily for 12 weeks

Study summary

The aim of this clinical study is to evaluate the efficacy and tolerability of probiotics on atrial fibrillation recurrence.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Female or male aged 40 years or above with BMI less than 40 2. Persistent AF patients directly after cardioversion Exclusion Criteria: 1. History of probiotic supplementation in the previous 6 weeks 2. Autoimmune diseases 3. Ongoing treatment with immunosuppressive therapies 4. Active Infection 5. Pregnant or breast-feeding patients 6. Active participation in another clinical study 7. History of or known allergy or intolerability to the study medications

Primary outcome measure(s)

  • Atrial Fibrillation Recurrence — 7 days

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University's Hospital Cairo Egypt

More Ain Shams University trials in Egypt

Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure Recruiting
3D Analysis of Soft Tissue Healing After Immediate Implant Placement Using PRF Vs HAM Active, not recruiting
Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival Recruiting
Efficacy of Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Serratus Anterior Plane Block for Postoperative Pain Control Following Video-assisted Thoracoscopic Surgeries (VATS): Randomized Control Trial Recruiting
Effect of Kangaroo Mother Care on Energy Utilization in Preterm Neonates Active, not recruiting

Other trials for the same condition

Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07568964 on ClinicalTrials.gov ↗ ← All trials in Egypt